Researchers analyzed data from several studies involving patients with advanced or metastatic Esophageal Squamous Cell Carcinoma (ESCC). The study looked at the effectiveness of combining two drugs, camrelizumab and apatinib, specifically comparing those who had never received prior treatment to those who had been pretreated.
The results showed that patients who were treatment-naive had a much higher one-year survival rate of 95 percent compared to 55 percent for those who were pretreated. These patients also showed significantly higher response rates and better progression-free survival. While the combination was effective, some side effects like leukopenia and anemia occurred in both groups.
Because this is a meta-analysis of several studies rather than one large trial, the findings are promising but need more validation. Larger trials are needed to confirm these results before they can change standard care. Patients should discuss these specific drug combinations and their potential benefits with their oncology team.
